ssio 2019

Topics to be addressed (2nd Summer School on Cancer Immunology and Immunotherapy)

  • Unrelated stem cell donors for the treatment of haematological malignancies
  • Translating old discoveries into tomorrow’s cancer immunotherapy
  • T-cell therapy- bringing discovery into the clinic
  • TCR structure and function – Clinical trials
  • Tumor ablation and immune stimulation
  • Targeting xCT in metastatic breast cancer treatment
  • NSCLC: updated data with ICIs
  • Immunotherapy for the treatment of urothelial cancer
  • Biomarkers and immune resistance
  • T-cell suppression by cancer cells; off the beaten track
  • The role of myeloid-derived suppressor cells in tumor immune evasion
  • Modulation of immune responses via PD-L1 targeting
  • Immune escape and resistances to immune check point inhibitors
  • Ageing and the human immune system in the era of cancer immunotherapy: is it all downhill?
  • The Melanoma paradigm for anti-cancer immunotherapy
  • Immune biomarkers
  • Immunotherapy beyond anti-PD1/PDL1
  • The (tremendous) gap between predicted epitopes and those actually recognized by CD8 T cells
  • T-cell monitoring for clinical studies: main techniques, pitfalls and quality assurance
  • Immune check point inhibitors for the treatment of the head and neck cancer
  • Management of immune related toxicity